Certara (NASDAQ:CERT) Issues FY 2025 Earnings Guidance

Certara (NASDAQ:CERT - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.420-0.460 for the period, compared to the consensus estimate of 0.450. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $420.0 million.

Analyst Ratings Changes

A number of brokerages have issued reports on CERT. Barclays reduced their price objective on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. KeyCorp increased their price target on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday. Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Stephens reiterated an "overweight" rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Finally, William Blair restated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.17.

Certara Stock Up 4.6 %

Shares of NASDAQ:CERT traded up $0.62 on Friday, hitting $14.15. 2,114,112 shares of the company traded hands, compared to its average volume of 1,188,632. The stock has a 50 day simple moving average of $11.62 and a 200-day simple moving average of $11.46. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.28 billion, a PE ratio of -70.75, a PEG ratio of 9.29 and a beta of 1.64. Certara has a 52 week low of $8.64 and a 52 week high of $17.94.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.